Scrip | What Does 2022 Hold For Biopharma?
Originally published by SCRIP on February 8 , 2022.
James West, Director in Lincoln’s Healthcare Group shares that there has been increased private equity firm’s interest in the Biopharma space and expects continued activity in this sphere for the year 2022 .
James West, Director at Lincoln International's Healthcare Group speaks with Scrip on Biopharma market and trends for 2022.
- Sign up to receive Lincoln's perspectives
In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners
Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More
In Q3 2020, Lincoln International introduced Lincoln’s Latest video series. Experts from across industries, services and geographies, share perspectives on current trends, recent observations and future outlooks through this video… Read More
Surging Medical Inflation Fuels Continued Interest in Self-Funding and Cost Containment
During the past 18 months, inflation has accelerated to levels not seen since the early 1980s. The cost of energy, food and other staples has increased rapidly and is expected… Read More
Lincoln International Expands Presence to Southeast, Opening Miami and Atlanta Offices
Continued growth spurs openings in new geographies for both client coverage and talent acquisition Lincoln International announced today that it has expanded its U.S. footprint with the opening of offices… Read More
Recent Transactions in Healthcare
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Lincoln International advised EverVet Partners, a portfolio company of Tailwind Capital, on receiving a significant investment from Freeman Spogli & Co.
Lincoln International has advised All About Children on its sale to Partou, a portfolio company of Waterland Private Equity
Lincoln International advised SEKISUI CHEMICAL on the sale of SEKISUI XENOTECH to BioIVT, a portfolio company of Linden Capital Partners